Ayala Pharmaceuticals, Inc. (AYLA)
Stock Price:
$12.71 USD
0.07 (0.55%)
Updated Sep 22, 2020 12:37 PM EDT - Market open
Key Info
| Market Cap |
162.41M |
| Revenue (ttm) |
3.26M |
| Net Income (ttm) |
n/a |
| Shares Out |
12.78M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 22, 2020 |
| Last Price |
$12.71 |
| Previous Close |
$12.64 |
| Change ($) |
0.07 |
| Change (%) |
0.55% |
| Day's Open |
12.53 |
| Day's Range |
12.60 - 13.21 |
| Day's Volume |
2,538 |
| 52-Week Range |
8.62 - 16.50 |
More Stats
| Market Cap |
162.41M |
| Enterprise Value |
104.97M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
12.78M |
| Float |
3.00M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1,983 |
| Short Ratio |
3.45 |
| Short % of Float |
0.28% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
49.77 |
| PB Ratio |
3.45 |
| Revenue |
3.26M |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
57.44M |
| Net Cash / Share |
4.49 |
| Gross Margin |
32.15% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-46.93% |
| ROE |
-91.70% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
2 |
| Overweight |
1 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$21.12*
(66.18% upside)
Low
12.5
Current: $12.71
High
25.0
Target: 21.12
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 2.33 | - |
| Gross Profit | 1.05 | - |
| Operating Income | -17.71 | -9.04 |
| Net Income | -17.79 | -8.87 |
| Shares Outstanding | 4.98 | 4.94 |
| Operating Cash Flow | -14.95 | -6.37 |
| Capital Expenditures | -1.33 | -0.22 |
| Free Cash Flow | -16.28 | -6.59 |
| Cash & Equivalents | 16.81 | 26.26 |
| Net Cash / Debt | 16.81 | 26.26 |
| Assets | 20.05 | 27.13 |
| Liabilities | 58.97 | 48.98 |
| Book Value | -38.92 | -21.86 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Ayala Pharmaceuticals, Inc. |
| Country |
Israel |
| Employees |
31 |
| CEO |
Roni Mamluk |
Stock Information
| Ticker Symbol |
AYLA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AYLA |
| IPO Date |
May 8, 2020 |
Description
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.